Get started
ReutersReuters

Inhibikase Therapeutics Announces Closing Of $10 Million Concurrent Registered Direct Offering And Private Placement Priced At A Premium To Market Under Nasdaq Rules

IKT

Inhibikase Therapeutics Inc IKT:

  • INHIBIKASE THERAPEUTICS ANNOUNCES CLOSING OF $10 MILLION CONCURRENT REGISTERED DIRECT OFFERING AND PRIVATE PLACEMENT PRICED AT A PREMIUM TO MARKET UNDER NASDAQ RULES

Login or create a forever free account to read this news